AceLink is advancing a small-molecule treatment option for Fabry disease, which could provide a more convenient alternative ...
In addition to the Fabry disease program, Sangamo's diverse pipeline includes isaralgagene civaparvovec (ST-920 or isa-vec), a gene therapy program, and STAC-BBB, an innovative approach targeting ...
LEXINGTON, Mass. - uniQure N.V. (NASDAQ: NASDAQ:QURE), a gene therapy company with a market capitalization of $767 million, ...
In addition to the Fabry disease program, Sangamo's diverse pipeline includes isaralgagene civaparvovec (ST-920 or isa-vec), a gene therapy program, and STAC-BBB, an innovative approach targeting the ...
Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...
Sangamo (SGMO) announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene ...
Sangamo (SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate ST-920 in the treatment of Fabry disease. Read more here.
PLX READ THE FULL PLX RESEARCH REPORT Reasons To Own / A Compelling Idea for 2025 Protalix Biotherapeutics, Inc. (NYSE:PLX) ...
Qure (QURE) announced the completion of enrollment in the first cohort of the Phase I/IIa trial of AMT-191, an investigational gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback